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Berberine is known to inhibit the diﬀerentiation of 3T3-L1 cells in vitro, improve glycemic control, and attenuate dyslipidemia in
clinical study. The aim of this study was to investigate the eﬀects of berberine on preadipocytes isolated from human omental fat
and in metabolic syndrome patients treated with berberine for 3 months. We have shown that treatment with 10μM berberine
resulted in a major inhibition of human preadipocyte diﬀerentiation and leptin and adiponectin secretion accompanied by
downregulationofPPARγ2,C/EBPα,adiponectin,andleptinmRNAexpression.After3monthsoftreatment,metabolicsyndrome
patients showed decrease in their BMI (31.5 ± 3.6v e r s u s2 7 .4 ± 2.4kg/m 2) and leptin levels (8.01 versus 5.12μg/L), as well as
leptin/adiponectin ratio and HOMA-IR. These results suggest that berberine improves insulin sensitivity by inhibiting fat store
and adjusting adipokine proﬁle in human preadipocytes and metabolic syndrome patients.
1.Introduction
The metabolic syndrome is a cluster of multiple metabolic
diseases based on obesity and insulin resistance. Obesity
leads to insulin resistance and a proatherogenic state.
Therefore,theroleofobesity,especiallyvisceral(orcentralor
abdominal) obesity, is believed to be the main physiological
force resulting in disorders of glucose and lipid metabolism
in metabolic syndrome [1]. However, because of the eﬀects
of insulin in fat cell diﬀerentiation and metabolism of
glucose and lipids, patients who are treated by insulin,
sulphonylureas, and thiazolidinediones may suﬀer from
varying degrees of weight gain. Eﬀects of metformin on body
weight may be based on calorie intake reduction rather than
energy consumption increased. The statins for regulating
lipid metabolism are generally expensive and some of them
have liver toxic side eﬀects. Therefore, the search for a
cost/eﬀective drug that can not only lower blood glucose
and lipids but also reduce weight for metabolic syndrome
treatment has a signiﬁcant importance.
Berberine is an isoquinoline derivative alkaloid isolated
from many kinds of medicinal herbs, such as Hydrastis
canadensis (goldenseal), Cortex Phellodendri (Huangbai),
and Rhizoma Coptidis (Huanglian). It is safe and cheap
and has been extensively used as an antibacterial drug
[2]. Berberine has been proven to have many other phar-
macological eﬀects including antimicrobial [3], antitumor
[4], anti-inﬂammation [5], blood glucose lowering [6],
and even inhibiting chronic cocaine-induced sensitization
[7]. In one recent single-blind clinical observation, the
study showed that diet supplementation of some natural
substances including berberine was beneﬁcial for correcting
lipid metabolism disorders and reducing cardiovascular risk
factors [8]. However, the body weight reduction eﬀect is
poorly characterized in clinical study.
Pharmacokinetics of berberine indicates that adipose tis-
sue is its main target [9]. Adipose tissue is a huge energy
reserve organ. The excessive proliferation and diﬀerentiation
of fat cells can lead to excessive fat accumulation in adipose
tissue,resultinginobesity[10].Atthesametime,fatcellscan2 Evidence-Based Complementary and Alternative Medicine
secrete a variety of hormones, named adipokines, through
endocrine, paracrine, and autocrine mechanisms that aﬀect
energy metabolism of the body [11]. It is assumed that unfa-
vorable changes in the secretion of adipokines, considered
as an early symptom of impaired adipose tissue function,
are the potential link between obesity and insulin resis-
tance, inﬂuencing the development of metabolic syndrome
[12]. Leptin and adiponectin are the key biomarkers of
adipose tissue. Hyperleptinemia and hypoadiponectinemia
are common in obesity. They reﬂect increased adiposity
and may contribute to hypertension, dyslipidemia, impaired
glucose metabolism, and proatherogenic state in obesity
and metabolic syndrome [13, 14]. Many studies have been
published on the mechanism of berberine’s eﬀect on adipose
tissue.Zhouetal.foundthatberberinesigniﬁcantlyinhibited
diﬀerentiation of mouse 3T3-L1 preadipocytes into fat
cells [15]. In addition, it has also been shown to reduce
leptin and resist secretion [16] and increase the mRNA
expression of adiponectin [17]. Members in our research
team, Zhang et al. also found berberine-moderated glucose
and lipid metabolism through a multipathway mechanism
that includes AMP-activated protein kinase- (AMPK-) p38
MAPK-GLUT4, JNK pathway, and PPARα pathway in KKAy
mice [18]. These results showed that berberine may have
excellent potential as an agent to prevent metabolic syn-
drome. However, these studies were performed in rodent
models or murine cell lines. The eﬀects of berberine on
human adipose tissue are rarely reported. Due to lack of
well-established human adipocyte model, human primarily
cultured preadipocytes have been particularly useful for
verifying the results obtained from the preadipocyte cell
lines. Thus, in this paper, we presented evidence obtained
from human primarily cultured omental preadipocytes as
well as from metabolic syndrome patients and demonstrated
that berberine improves insulin sensitivity by inhibiting fat
store and adjusting the proﬁle of adipokines.
2.MaterialsandMethods
2.1. Materials. Berberine used in vitro study was purchased
from Sigma Aldrich Co, St. Luis, MO, USA. Oral medication
berberine used in vivo study has Chinese Drug Approval
Number: H.M.L.N., H11022584.
2.2. Adipose Biopsies. Omental adipose tissue biopsies were
obtained from nine patients (3 females, 6 males, age range
22∼47 years) who underwent elective inguinal hernia repair
surgery. None of these patients suﬀered from endocrine
malignant or chronic inﬂammatory diseases or severe sys-
temic illnesses or any recent weight change. None were
taking medications known to aﬀect adipose tissue mass or
metabolism. The study was approved by the local ethical
committee. All patients gave their informed consent. On
the day of surgery, all patients fasted for at least 6h pre-
operatively, and all underwent general anesthesia. Adipose
tissue specimens from the omental adipose tissue regions
were obtained within 30–45min after the onset of surgery.
In general, 10–15g of adipose tissue was obtained and trans-
ported to the laboratory in normal saline (transport time
with 10min). Specimens from three patients were used for
cell proliferation experiments and six for cell differentiation
studies.
2.3. Cell Culture. The isolation and culture of preadipocytes
was performed according to the method described elsewhere
by ourselves [19].Brieﬂy,Adiposetissuewascutinto1mm ×
1mm pieces with ophthalmic scissors. Collagenase digestion
was performed at 37◦C on a shaking platform (200rpm)
for 1 to 3 hours. Next, digest was transferred to ﬁlter by
74μm sieve size ﬁlter. This procedure was repeated until
the complete digestion was ﬁltered. The cell suspension was
centrifuged at 480g for 5min, and the preadipocyte fraction
was resuspended in growth medium (PromoCell, Germany).
Then cells were counted and cultured in diﬀerent mediums
at 37◦C in a humidiﬁed 5% CO2 atmosphere.
2.4. Analysis of Cell Proliferation. 4 × 103 preadipocytes/well
were inoculated into 96-well plates and cultured in growth
medium supplemented with varying concentrations of
berberine (0μM, 0.1μM, 1μM, and 10μM). Proliferation
was determined by MTT assay after 1, 2, and 3 days of
culture. Brieﬂy, after culture medium was removed, MTT
(0.5mg/mL, 50μL/well) was added into the plates and
incubated at 37◦C for 4h, followed by the addition of
DMSO (150μL/well), and incubated at 37◦Cf o r1h o u r .T h e
proliferation values were obtained from the optical density
(OD) measured at 570nm with 650nm as background. Data
are presented as percentage of the untreated controls (0μM
berberine) at each time point.
2.5. Analysis of Cell Diﬀerentiation. 5 × 104 cells/well cells
were inoculated in 24-well plates. After 48 hours, cells
were induced to diﬀerentiate in diﬀerentiation medium
(PromoCell, Germany) containing varying concentrations of
berberine (0μM, 0.1μM, 1μM, and 10μM). After 16 days,
the degree of diﬀerentiation was determined by Oil-Red-
O staining performed as previously reported [20]. In brief,
medium was removed and cells were washed with PBS twice,
ﬁxed with 3.7% formalin at room temperature for 30min,
added 60% 2-propanol and incubated for 5min, then moved
out 2-propanol and stained cells with Oil-Red-O solution
(Sigma, USA) at room temperature for 10min. Images were
obtained using an Olympus IX70 inverted phase-contrast
microscopy (Olympus, Japan). After staining, the cells were
washed twice with 70% ethanol and dissolved in 2-propanol
containing 4% Nonidet-P40. OD values were measured at
an absorbance of 490nm using a standard microtiter reader
(Bio-Rad, Canada).
2.6. RT-PCR Analysis. 5 × 105 cells/well cells were seeded in
6-well plates. 8 days after diﬀerentiation, 10μM berberine
was added in diﬀerentiation medium. Cells were harvested
for 24 hours afterwards and mRNAs were extracted with
Trizol reagent (Invitrogen, USA). RNA recovery and quality
were checked by measuring the 260/280nm optical density
ratio and by electrophoresis on 1.5% agarose gel. 1μgo f
total RNA from each sample was used for reverse tran-
scription reaction using the TaqMan reverse transcriptionEvidence-Based Complementary and Alternative Medicine 3
reagents (Applied Biosystems, USA). The expression levels
of peroxisome proliferator-activated receptor γ2( P P A R γ2),
CCAAT enhancer-binding protein α (C/EBPα), lipoprotein
lipase, leptin, and adiponectin were measured using the
following oligonucleotides (Shanghai Biotechnology Engi-
neering Service Co. Ltd., China): 5 -GTG/GGG/CGC/CCC-
/AGG/CAC/CA-3  and 3 -CTT/TAG/CAC/GCA/CTG/T-
AA/TTC/CTT/C-5  primers for β-actin; 5 -ACC/CTG/T-
GC/GGA/TTC/TTG/TGG/CTC/TGT-3  and 3 -CGA/AG-
T/CCG/ATG/AGG/TGT/CTC-5  primers for leptin; 5 -
CTG/GGA/GCT/GTT/CTA/CTG/C-3  and3 -AGT/CAC/C-
CT/AAC/CTC/GT-5  primers for adiponectin; 5 -GCG-
/ATT/CCT/TCA/CTG/ATA/CAC-3  and 3 -CGG/ACG/T-
AG/AGG/TGG/AAT/AAT-5  primers for PPARγ2; 5 -GCA-
/AGG/CCA/AGA/AGT/CGG/TGG/AC-3  and 3 -GAG/GA-
A/CCA/GTT/CCG/GTA/CCC/GT-5  primers for C/EBPα;
5 -ACA/CAG/CTG/AGG/ACA/CTT/GC-3  and 3 -GAG-
/TCC/TCG/TAA/TGG/GTC/AC-5  primers for lipoprotein
lipase. The basic reaction conditions are as follows: DNA
denaturation at 94◦C for 5min; PCR ampliﬁcation: 94◦C
denaturation for 50sec, speciﬁc annealing temperature for
50sec, 72◦C extension for 1min, and ﬁnal extension also at
72◦C for 8min. To ensure that ampliﬁcation of these prod-
ucts was within the exponential range, diﬀerent numbers
of PCR cycles (25–40 cycles) were run. PCR products were
sent to Shanghai Biotechnology Engineering Service Co. Ltd.
for sequence veriﬁcation. PCR products were analyzed on a
2% agarose gel, and semiquantitative analysis was performed
(quantiﬁcation with Bio-1D software, France).
2.7. Eﬀects of Berberine on Secreted Proteins in the Human
Preadipocyte Diﬀerentiation Process. 105 cells/well cells were
inoculated in 12-well plates. Cells were induced with diﬀer-
entiation medium. Beginning on the third day, supernatants
were collected every 2 days and the ﬁnal collections were
done after 21 days of diﬀerentiation. Leptin and adiponectin
proteinsweremeasuredusingcommercialELISAkits(Quan-
tikine, R&D Systems, Germany). The intra- and interassay
CVs for leptin were <3.3% and <5.4%, respectively; the
intra- and interassay CVs for adiponectin were <5.0% and
<7.9%, respectively.
2.8. Clinical Intervention Study. 41 patients (age ranged 32∼
68years)withnewlydiagnosedmetabolicsyndromeenrolled
in this study. 3 of them were initiative to withdraw from
the study on medication 1, 3, and 6 days, and 1 person
lost contact. In the end, 37 people (17 males/20 females)
ﬁnished the clinical trials. Metabolic syndrome was deﬁned
according to Chinese Diabetes Society deﬁnition set in
2004 [21]. The study had the approval of the local ethical
committee, and informed consent was obtained from all
patients. Patients were treated with berberine 0.3g three
times a day for 12 weeks, and the following indicators
before and after treatment were measured: height, weight,
waist circumference, fasting plasma glucose, fasting insulin,
hemoglobin A1C (HbA1c), triglyceride, cholesterol, LDL
cholesterol, high-density lipoprotein, adiponectin, and lep-
tin. The following were calculated: BMI, Leptin/Adiponectin
ratio,andhomeostasismodelofassessmentinsulinresistance
index [HOMA-IR = fasting insulin (mIU/L) × fasting
glucose (mmol/L) /22.5].
2.9. Statistical Analysis. Descriptive statistics and analysis
were performed in SPSS 13.0 for Windows (SPSS Inc.
Chicago, IL). t-tests of two independent samples were done
to determine the mean comparison in cell study (test of
homogeneity of variance, such as P<0.10, line t-test), and
t-test of paired measurement data was done in clinical study
before and after medication. Data of normal distribution
were expressed as means ± the standard deviation. Data of
nonnormal distribution were expressed as median (M) and
quartile (Q1/4). The α level was set at 0.05.
3. Results
3.1. Omental Preadipocytes and Induced Mature Adipocytes.
Human omental preadipocytes were isolated and primarily
cultured in growth medium. After 3-4 days, these cells
began to show the typical long spindle shape (Figure 1(a))
and started to proliferate. Preadipocytes were induced to
diﬀerentiate, and morphological changes can be observed
after 15 days. When preadipocytes gradually mature, their
cytoplasm was ﬁlled with lipid droplets, and small lipid
droplets were integrated into big lipid droplets (Figure 1(b)).
Fat droplets in adipocytes can be observed in the cytoplasm
by Oil-Red-O staining (Figure 1(c)).
3.2. Eﬀect of Berberine on Human Preadipocyte Proliferation.
Primary human omental preadipocytes were treated with
diﬀerent concentrations of berberine and OD values were
measured at day 1, day 2, or day 3. Results show that the
relative OD values are signiﬁcantly higher when berberine
was added at 0.1μM, 1μM, and 10μM concentrations
compared with the control group (P<0.05) (Figure 2).
Nosigniﬁcantdiﬀerencewasfoundamongberberine-treated
groups (P>0.05).
3.3. Eﬀect of Berberine on Human Preadipocyte Diﬀerentia-
tion. Diﬀerentconcentrationsofberberinewereusedduring
the cell diﬀerentiation process, and cells’ morphological
changes through Oil-Red-O staining were observed at day
16. Cell density was reduced judging by the stained color per
increasing drug concentrations at low magniﬁcation ﬁeld of
vision.Thissuggeststhatberberineinhibitstheprocessofcell
diﬀerentiation and hypertrophy (Figure 3(a)). The staining
intensity was measured. OD values of the berberine groups
atconcentrationsof1μMand10μMweresigniﬁcantlylower
than of the control groups, and the decreases determined
were dose dependent (P<0.05) (Figure 3(b)).
3.4. Eﬀect of Berberine on PPARγ2, Lipoprotein Lipase,
C/EBPα, Leptin, and Adiponectin mRNA Expression. Pre-
adipocytes were induced to diﬀerentiate over 8 days, then
10μM berberine was added and cells were harvested for 24
hours. The expression levels of PPARγ2, lipoprotein lipase,
C/EBPα, leptin, and adiponectin were measured by RT-
PCR. For quality control, the resulting PCR products were
sequenced in duplicate and showed >85% homology with4 Evidence-Based Complementary and Alternative Medicine
(a) (b) (c)
Figure 1: Representative phase-contrast images of human omental preadipocytes in primary culture and diﬀerentiated preadipocytes.
(a) Human omental preadipocytes in primary culture, (b) mature adipocytes induced from preadipocyte diﬀerentiation, and (c) mature
adipocytes stained with Oil-Red-O, ×200.
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Figure 2: Eﬀect of berberine on human preadipocyte proliferation.
C e l l sw e r ec u l t u r e di ng r o w t hm e d i u mw i t hd i ﬀerent concentra-
tions of berberine for 1, 2, and 3 days. At each culture time point,
proliferation capacity was determined by MTT assay. Values are
expressed as percentage of the untreated controls and represent the
mean ± SEM of the three separate experiments in eight replicates.
∗P<0.05, compared to control at each time point.
GenBank registration sequences. Comparison of the ratio of
the gray degree between the speciﬁc gene band and internal
reference β-actin band showed that 10μM of berberine
inhibits PPARγ2, lipoprotein lipase, C/EBPα, adiponectin,
and leptin mRNA expression (Figures 4(a) and 4(b)).
3.5. Eﬀect of Berberine on Leptin and Adiponectin Secretion
during the Process of Preadipocyte Diﬀerentiation. When
preadipocytes were cultured with growth medium, a very
low level of leptin protein was detected. However, the levels
did not change with time. No adiponectin secretion can be
detected.Oncepreadipocyteswereculturedindiﬀerentiation
medium, the secretion of leptin increased gradually with
time. It increased much more rapidly after day 9 and reached
the peak at day 17∼19. After that, it maintained a high
level of secretion. The secretion of adiponectin was also
diﬀerentiation induced, and at day 7, low levels of secretion
can be detected. This was the time when fat cells containing
lipid droplets can be seen under microscope. After 15∼17
days, adiponectin secretion reached its peak; however, it
began to decrease signiﬁcantly at day 21 (P<0.05). For the
10μM berberine-treated diﬀerentiation medium group, the
levels of leptin and adiponectin secretion were signiﬁcantly
reduced starting from day 9 and remained low until day 21
(from mid- to terminal stages of diﬀerentiation) (Figure 5).
3.6. Eﬀects of Berberine on the Impact Clinical Markers.
Patients with newly diagnosed metabolic syndrome were
treated with berberine for 12 weeks. Their BMI, waist cir-
cumference, fasting plasma glucose, fasting insulin, HbA1c,
triglyceride, total cholesterol, LDL cholesterol, leptin, the
ratio of leptin and adiponectin, and HOMA-IR were mea-
sured before and after the treatment. All of those indexes
showed a decreasing trend, with a signiﬁcant statistical dif-
ference (P<0.05–0.01). However, the levels of adiponectin
did not change signiﬁcantly (Table 1).
3.7.Safety. Noneofthepatientsexperiencedseveregastroin-
testinaladverseeventswhenberberinewasused.Incidenceof
gastrointestinal adverse events was mainly constipation (n =
1; percentage, 5%). The adverse eﬀect disappeared when
berberine dosage was decreased from 0.3g three times a day
to 0.2g three times a day. Liver and kidney functions were
monitored in this study. No signiﬁcant changes of plasma
ALT,γ-GT,andcreatininewereobservedduringthe12weeks
of berberine treatment (Table 1). None of the patients were
observed with hypoglycemia.
4. Discussion
Proliferation and diﬀerentiation are two important aspects
in fat tissue development. In our experiment, we have
shownthatberberinehasagrowth-factor-likeroleonhuman
preadipocytes, promoting cell proliferation. Our result isEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: Eﬀect of berberine on human preadipocyte diﬀerentiation. Cells diﬀerentiated in the absence or presence of diﬀerent
concentrations of berberine over 16 days. The degree of diﬀerentiation was determined by Oil-Red-O staining. (a) Photomicrographs
representing cells maintained in diﬀerent concentrations of berberine: (A) control, (B) 0.1μM berberine, (C) 1μM berberine, (D) 10μM
berberine, ×100. (b) Absorbance value representing the mean ± SEM of the three separate experiments in six replicates. ∗P<0.01,
comparison between berberine-treated groups and control group, †P<0.05, comparison among berberine-treated groups.
consistent with previous studies showing that berberine can
promote the proliferation of mouse 3T3-L1 preadipocyte
[22]. Adult obesity is mainly due to the increased volume
of fat cells which are abnormally hypertrophic [23]. Our
in vitro experiments showed that berberine signiﬁcantly
inhibited the omental preadipocytes to become mature
adipocytesjudgingbytheirmorphologyorlipid-speciﬁcOil-
Red-O staining. Therefore, berberine has potential clinical
application in reducing visceral fat and controlling central
obesity. It has been reported that fat tissue composed of
a higher amount of small fat cells is more sensitive to
insulin compared with fat tissue with the same lipid content
composed of a small number of large fat cells, and also
the former has very little inﬂammatory responses [24]. Our
results showed that berberine can promote human fat cell
proliferation and inhibit fat cell enlargement, indicating
that it may be able to reduce inﬂammation responses,
improve insulin sensitivity of visceral adipose tissue, and
reduce or eliminate the visceral adipose tissue. Moreover,
our in vivo study also showed that, after taking berberine
for three month, patients with metabolic syndrome were
found to reduce their waist circumferences and BMI to
varying degrees. This positive result therefore seems in good
agreement with the in vitro study.
The nuclear receptor PPARγ and members of the C/EBP
family take important roles in adipogenesis [25], and the
major players are PPARγ2[ 26] and C/EBPα [27]. Many
studies have showed that berberine inhibited the mRNA and
protein levels of adipogenesis-related transcription factors
PPARγ2 and C/EBPα [28, 29]. We studied the eﬀect and
transcriptional impact of berberine on human preadipocyte
diﬀerentiation. Our result showed that the berberine can
inhibit PPARγ2 and C/EBPα mRNA expression simul-
taneously during the human preadipocyte diﬀerentiation
process. Recently, the transcription factors GATA binding
protein 2 and 3 (GATA-2 and GATA-3) have been shown to
be important gate keepers of the diﬀerentiation process [30,
31]. Studies from HU et al. showed that berberine increases
expression of GATA-2 and GATA-3 during inhibition of
adipocyte diﬀerentiation in both murine cell lines 3T3-L1
and human white preadipocytes cell line. But contradic-
torily, they also found that the diﬀerentiation inhibition
mechanisms of berberine appeared to be independent of
PPARγ2 and C/EBPα in that human white preadipocyte cell
line while being dependent on decreasing of PPARγ2a n d
C/EBPα gene expression in 3T3-L1 lines [32, 33]. Those
results also seem to contrast with our ﬁndings from human
primarily cultured preadipocytes. Since there is still lack6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Eﬀect of berberine on PPARγ2, lipoprotein lipase, C/EBPα, leptin, and adiponectin mRNA expression in diﬀerentiated
preadipocytes analyzed using RT-PCR. (a) Digital photos of PCR products in agarose gel. Lane 1: control group, lane 2: 10μM berberine,
laneM:DNAmarkers.(b)Resultsareexpressedastheratiobetweentheintensityofbandcorrespondingtotargetgeneversusthattoβ-actin,
representing the mean ± SEM of the three separate experiments in triplicate. ∗P<0.05, compared to control.
of well-characterized human preadipocyte cell lines, further
studies in human primarily cultures are particularly needed
to clarify the results from those cell lines.
Lipoprotein lipase is a kind of glycoprotein synthe-
sized and secreted by fat cells. Current understandings of
lipoprotein lipase’s physiological functions are to decom-
pose chylomicrons and triglycerides into very low-density
lipoproteinsandtopromotethelipoproteintransferbetween
triglyceride phospholipids and apolipoproteins and so forth.
We found that berberine reduced lipoprotein lipase mRNA
expression in human fat cells which is consistent with the
recent study by Choi et al. showing that berberine reduces
mouse 3T3-L1 lipoprotein lipase mRNA expression [9].
As discussed by Kong et al. [34], oral administration of
berberine in 32 hypercholesterolemia patients for 3 months
reduced serum cholesterol by 29%, triglycerides by 35%, and
LDL cholesterol by 25%. Our clinical study of the eﬀects
of berberine on total cholesterol, triglycerides, and LDL
cholesterol along with analysis of liver and kidney adverse
reactions also indicates that berberine could be a cheap,
eﬃcient,andsafelipid-loweringdruginmetabolicsyndrome
patients.
Leptin and adiponectin have been shown to play an im-
portant role in insulin resistance. During the process ofEvidence-Based Complementary and Alternative Medicine 7
Table 1: The general information and laboratory data of the new diagnosed metabolic syndrome patients at the baseline and 12 weeks after
the therapy.
Before medication After medication P value
Participants (M/F) 37 (17/20) 37 (17/20)
Age (years) 41.1 ± 7.34 1 .1 ±7.3
Body mass index (kg/m2)3 1 .5 ± 3.62 7 .4 ±2.4 <0.01
Waist circumference (cm) 97.3 ±10.59 2 .1 ±9.10 0.04
Systolic pressure (mmHg) 146.1 ± 14.9 134.0 ±13.3 0.32
Diastolic pressure (mmHg) 95.5 ± 8.78 8 .5 ±10.3 0.24
Total cholesterol (mM) 6.69 ±1.04 5.74 ±0.84 0.03
High-density lipoprotein cholesterol (mM) 1.09 ±0.36 0.92 ±0.36 0.06
Low-density lipoprotein cholesterol (mM) 3.68 ±0.85 2.86 ±0.57 0.03
Triglyceride (mM) 3.03 ±2.05 1.86 ±0.90 <0.01
Fasting plasma glucose (mM) 7.37 ±0.72 6.13 ±0.85 0.03
HbA1c (%) 7.10 ±0.64 6.04 ±0.62 0.02
Leptin (ug/L) 8.01 (2.04∼15.17) 5.12 (1.88∼12.89) 0.04
Adiponectin (mg/L) 8.42 (4.75∼14.81) 10.02 (5.13∼15.59) 0.14
Leptin/adiponectin 0.76 (0.29∼2.85) 0.58 (0.14∼1.22) 0.02
Fasting insulin (mIU/L) 16.90 (11.6∼20.1) 12.50 (9.7∼14.8) 0.04
HOMA-IR 5.46 (3.62∼6.69) 3.25 (2.50∼4.58) 0.03
Glutamic-pyruvic transaminase (U/L) 37.28 ± 4.12 39.89 ±7.08 0.62
γ-Glutamyl transpeptidase (U/L) 48.71 ± 8.12 41.79 ±7.11 0.74
Creatinine (mM) 87.45 ± 4.71 89.11 ±8.07 0.77
t-test of paired measurement data comparisons between two comparing lines before and after medication. Data of nonnormal distribution were described
using the median (M) and quartile (Q1∼Q4).
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Figure 5: Eﬀect of berberine on leptin and adiponectin secretion
duringtheprocessofpreadipocytediﬀerentiation.Resultsrepresent
the mean values of the three separate experiments in triplicate.
preadipocytes diﬀerentiation, secretion of leptin and adi-
ponectin showed diﬀerent kinetics: in the ﬁrst phase low
levels of leptin secretion can be detected in fat cells, but no
adiponectin secretion can be detected. The amount of leptin
secretion continued to increase in a synchronized fashion
with the diﬀerentiation process, while the secretion of
adiponectinwasonlyobservedwhenpreadipocytesgradually
mature and their cytoplasm began to be ﬁlled with lipid
droplets. This result suggests that only mature fat cells can
secrete adiponectin which can be used as a speciﬁc marker
to determine the maturity of fat cells. In the midstages of
diﬀerentiation, secretion of leptin and adiponectin increased
with an increased number of fat cells; however, the rate of
increase in adiponectin was more obvious. In the late stages
of diﬀerentiation (at day 17–21), a morphological change
of the cells showed that the majority of cells diﬀerentiated
into fat cells with their cytoplasm ﬁlled with large lipid
droplets. Oil-Red-O staining showed that lipid content in
the cytoplasm remained at a steady high level. At this point,
leptin secretion remained at high levels, while adiponectin
secretion was seen to show a clearly downward trend. This
diﬀerence suggests that fat cells in diﬀerent fat-storing states
secrete leptin and adiponectin diﬀerently, which may also
reﬂect on their functional diﬀerences. The diﬀerentiation
stages of fat cells from clinically obese patients may be diﬀer-
ent from normal people. In obese patients, the fat cells may
showahigh-leptinandlow-adiponectin secretionpattern.In
our diﬀerentiation experiment, berberine not only inhibited
the diﬀerentiation and maturation of preadipocytes but also
suppressed leptin and adiponectin secretion. This suggests to
us that, in the visceral adipose tissue accumulation process,
berberine has a role in endocrine function regulation and
can promote the reversion of the initial process of fat storing.
Our clinical observation showed that in patients with newly
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signiﬁcantly with berberine treatment after 3 months. This is
diﬀerent from results shown in rat studies and may reﬂect
species diﬀerences. This may suggest that berberine has
the potential for anticentral obesity and regulating obesity-
related endocrine dysfunctions, thus achieving a balance
betweenfatcellfactors.Studieshavereportedthattheratioof
leptin and adiponectin reﬂects the body’s insulin resistance
[35]. We have conﬁrmed that berberine reduces HOMA-
IR and the ratio of leptin and adiponectin. As it inhibits
PPARγ2 mRNA expression and has more eﬀects on weight
loss and reducing leptin levels, berberine regulates insulin
sensitivity with a mechanism diﬀerent from the insulin
sensitizer, thiazolidinediones. Thus, berberine provides an
additional way for clinical treatment of metabolic syndrome
and obesity-related diseases. However, our experiment is
only a preliminary study on the mechanisms of eﬀects of
berberine on serum adipokines. A large-scale clinical study is
ideally required to include diﬀerent population groups and
more experiments concerning the mechanism details.
In conclusion, in order to explore the mechanism of
berberine’s role in improving insulin sensitivity, we used
human adipose tissue as material, focusing on the prolif-
eration, diﬀerentiation, and adipokine secretion of human
preadipocytes. We tried to ﬁnd clues from the in vitro
experiments and then veriﬁed them in clinical trial. Our
clinical study has some limitations relative to the random-
ized, placebo-controlled clinical design. However, our result
is in agreement with the ﬁndings from previous large sam-
ple, well-designed clinical studies [23, 34], indicating that
berberine improves glucose and lipid metabolism disorders.
Moreparticularly,weﬁndthatberberinecanimproveinsulin
sensitivitybyadjustingadipokinesecretionbothinprimarily
cultured preadipocytes as well as in metabolic syndrome
patients, and this was not well characterized in previous
human studies.
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